Skip to Content
Merck

L9664

Loratadine

≥98% (HPLC), Histamine H1 receptor antagonist, powder

Synonym(s):

4-(8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester, Loratidine

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C22H23N2O2Cl
CAS Number:
79794-75-5
Molecular Weight:
382.88
UNSPSC Code:
12352200
PubChem Substance ID:
24278525
NACRES:
NA.77
MDL number:
MFCD00672869

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Loratadine, ≥98% (HPLC), powder

SMILES string

CCOC(=O)N1CC\C(CC1)=C2/c3ccc(Cl)cc3CCc4cccnc24

InChI key

JCCNYMKQOSZNPW-UHFFFAOYSA-N

InChI

1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3

assay

≥98% (HPLC)

form

powder

color

white

solubility

DMSO: soluble 50 mg/mL
H2O: insoluble

originator

Schering Plough

storage temp.

2-8°C

Quality Level

200

Gene Information

human ... CYP3A4(1576), HRH1(3269), KCNH1(3756), KCNH2(3757), PTAFR(5724)
rat ... Hrh1(24448)

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Loratadine is a non-sedating histamine H1-receptor antagonist. Shown to inhibit the two-pore domain potassium channel K2P18.1 (also called TRESK or KCNK18).
Non-sedating histamine H1-receptor antagonist.

Features and Benefits

This compound was developed by Schering Plough. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
SLCH2255
SLCG2985
SLCF8955
SLCF7249
SLCF5480

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

F M Baroody et al.
Allergy, 55 Suppl 64, 17-27 (2001-04-09)
The primary mechanism of antihistamine action in the treatment of allergic diseases is believed to be competitive antagonism of histamine binding to cellular receptors (specifically, the H1-receptors), which are present on nerve endings, smooth muscles, and glandular cells. This notion
Karsten Weller et al.
Acta dermato-venereologica, 93(2), 168-174 (2012-10-12)
Non-sedating H1-antihistamines are the recommended first-line treatment for chronic spontaneous urticaria. While efficacy studies usually apply continuous daily treatment regimens, many patients take their medication on demand. In this randomized, double-blind trial we tested whether on-demand H1-antihistamine desloratadine in standard
P Deep et al.
Synapse (New York, N.Y.), 34(4), 313-318 (1999-10-26)
The efficacy of amantadine in alleviating motor symptoms of Parkinson's disease may be mediated in part by stimulation of cerebral dopa decarboxylase (DDC) activity, secondary to antagonism of N-methyl-D-aspartate (NMDA) type glutamate receptors. We tested the specific hypothesis that amantadine
F Estelle R Simons et al.
The Journal of allergy and clinical immunology, 110(5), 777-783 (2002-11-06)
The extent of the distribution of H(1)- antihistamines into the skin and H(1)-antihistamine activity in the skin are clinically relevant in the treatment of allergic skin disorders. In a prospective, randomized, double-blind, parallel-group, multiple-dose study, we gave fexofenadine 180 mg
M Magerl et al.
The British journal of dermatology, 166(5), 1095-1099 (2012-01-17)
Cold urticaria is a rare but severe and potentially lethal condition. It is primarily treated symptomatically with H(1) -antihistamines. However, patients have a variable response to these drugs and, to date, it has not been possible to predict readily the
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service